TERIFRAC 750MCG INJECTION 3 ML

TERIFRAC 750MCG INJECTION 3 ML is generally not recommended for individuals with a history of cancer, especially skeletal malignancies or bone metastases. The medication has been associated with an increased risk of osteosarcoma, and its safety in individuals with a history of cancer has not been well established.

Yes, TERIFRAC 750MCG INJECTION 3 ML can be used in men with osteoporosis. While osteoporosis is more commonly associated with women, men can also develop the condition. It can effectively increase bone density and reduce fracture risk in men with osteoporosis.

TERIFRAC 750MCG INJECTION 3 ML does not undergo significant renal excretion so it can be used in individuals with mild to moderate kidney impairment. However, caution is advised in individuals with severe kidney disease, as there is limited data on the safety and effectiveness of this medication in this population.

TERIFRAC 750MCG INJECTION 3 ML is commonly prescribed for individuals with a history of fragility fractures. Fragility fractures occur due to minimal trauma or impact and are often associated with osteoporosis. It helps to increase bone density and reduce the risk of future fractures in individuals with osteoporosis, including those who have previously experienced fractures.

TERIFRAC 750MCG INJECTION 3 ML is typically not used as a first-line treatment for osteoporosis. It is usually considered when other osteoporosis medications are ineffective, or individuals have a high fracture risk. However, whether it is appropriate as a first-line treatment depends on individual factors and should be discussed with your healthcare provider.

The long-term effects of TERIFRAC 750MCG INJECTION 3 ML have yet to be well understood, particularly beyond the recommended treatment duration of 2 years. The risk of osteosarcoma, a potential rare side effect, is one of the main concerns associated with long-term use.

TERIFRAC 750MCG INJECTION 3 ML may cause side effects, including common ones such as injection site reactions, nausea, dizziness, and headache. Serious side effects, though rare, can include the development of osteosarcoma, a type of bone cancer, and the potential for hypercalcemia, which can lead to symptoms like excessive thirst and muscle weakness.

It is essential to inform your healthcare provider about all prescription and non-prescription medications, vitamins, and herbal supplements you are currently taking before starting treatment with TERIFRAC 750MCG INJECTION 3 ML. This helps identify potential interactions.

Before using TERIFRAC 750MCG INJECTION 3 ML, discuss your full medical history with your doctor, especially if you have bone disorders other than osteoporosis, kidney problems (severe), hyperparathyroidism, or low blood pressure upon standing (orthostatic hypotension). It's generally not recommended if you have a history of bone cancer or metastases. Your doctor will monitor your blood calcium levels. The treatment duration is typically limited to 2 years, and it is not for children. If you are pregnant or breastfeeding, consult your doctor about the risks and benefits.

The main ingredient in TERIFRAC 750MCG INJECTION 3 ML is TERIPARATIDE.

Yes, TERIFRAC 750MCG INJECTION 3 ML is prescribed for the treatment of Osteoporosis.

Yes, TERIFRAC 750MCG INJECTION 3 ML is prescribed for conditions including Arthritis.

Terifrac should be avoided during pregnancy or breastfeeding unless absolutely necessary. Always consult your doctor for personalized advice.